No quarterly revenue total was found in BIOXYTRAN, INC.'s SEC filings.
Bioxytran, Inc. (BIXT) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-619,929
-1849.3% vs year-ago quarter
Operating cash flow
$-349,773
-377.9% vs year-ago quarter
Free cash flow
—
EPS
$-0.01
Dividend per share
None
Shares outstanding
114.70M
+28.9% vs year-ago quarter
Net cash
$-44,926
Q2 FY2025
Operating margin
5.5%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BIXT (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Needham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1445815
- Former names
- U.S. RARE EARTH MINERALS, INC. (until Oct 30, 2018); U.S. RARE EARTH MINERALS, INC (until Oct 3, 2018); U.S. Natural Nutrients & Minerals, Inc. (until Apr 14, 2011); AMERICA'S DRIVING RANGES, INC. (until Oct 29, 2009)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$654,600 | -$1.9M | -$607,285 | -$496,005 | -$224,077 |
| Net income | -$619,929 | -$2.1M | -$522,155 | -$282,726 | $35,439 |
| Diluted EPS | -$0.01 | -$0.02 | -$0.01 | $0.00 | $0.00 |
| Operating cash flow | -$349,773 | -$238,610 | -$236,971 | -$48,965 | -$73,196 |
| Total assets | $333,393 | $615,253 | $658,552 | $156,294 | $147,501 |
| Total liabilities | $5.3M | $5.0M | $3.2M | $3.1M | $2.8M |
| Stockholders' equity | -$4.9M | — | — | — | — |
| Cash and investments | $177,384 | $463,047 | $509,914 | $14,499 | $3,144 |
| Total debt | — | — | — | — | $48,070 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 5, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Aug 11, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Apr 15, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Unregistered share sale, Other events
|
Mar 20, 2026 | Mar 20, 2026 |
All 470 Bioxytran, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.